Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease
Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observedRocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory
Rocket Pharma's medicine RP-A501 worked safely in the first three patients being tested for a rare disease called Danon Disease. When a company's experimental medicine shows it's safe early on, that's a positive sign they might be on the right track, though lots more testing happens before we know if it actually helps patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.